GV20 Oncotherapy Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Shanghai China

Primary Industry

Healthcare Specialists

About

Established in 2016 and based in Shanghai, China, GV20 Oncotherapy is a company that focuses on selecting effective targets cancer drugs. It also develops approached to cancer diagnosis and therapy. The company has completed 3 rounds of funding as of 2021. The company mainly involved in the field of gene editing library screening, bioinformatics and big data analysis. The company main business is technology consulting, technology development, technology services, technology transfer in the fields of biotechnology and medical technology. The company have self developed GV20 unique platforms, GV20 genomics platform and GV20 AI (artificial intelligence) platform that provides a portfolio of immuno-oncology antibody drug solution for customers.

Current Investors

IDG Capital, Linear Venture, Wosheng Investment Management

Request a demo to show more

Primary Industry

Healthcare Specialists

Sub Industries

Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment

Website

www.gv20oncotherapy.com

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.